By Fineline Cube 
Sanofi SA (NASDAQ: SNY) announced that the European Commission (EC) has granted marketing authorization for Dupixent (dupilumab) to treat children aged 2 to 11 years with mild-to-moderate or severe chronic spontaneous urticaria (CSU) who have had an inadequate response to H1 antihistamines and have not received prior anti-immunoglobulin E (IgE) therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Approval Type | Full marketing authorization |
| Product | Dupixent (dupilumab) – monoclonal antibody |
| Indication | Treatment of CSU in children 2–11 years with inadequate response to H1 antihistamines |
| Approval Date | 14 Apr 2026 |
| Next Steps | Commercial launch across EU member states within Q2 2026 |
Drug Profile & Mechanism of Action
- Molecule: Fully human monoclonal antibody developed jointly by Sanofi and Regeneron Pharmaceuticals
- Target: Interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways
- Innovation: First and only biologic therapy approved for pediatric CSU, addressing the underlying type 2 inflammation driving the disease
- Intellectual Property: Protected by extensive patent portfolio covering composition, manufacturing, and multiple indications through 2037
Global Registration Status
Dupixent is now registered in more than 60 countries worldwide for treating various type 2 inflammatory diseases:
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic spontaneous urticaria (CSU)
- Chronic obstructive pulmonary disease (COPD)
Market Impact & Outlook
- EU Pediatric CSU Market: Estimated 50,000–70,000 eligible children across EU5 countries, representing a €200–300 million annual opportunity
- Revenue Forecast: Analysts project Dupixent sales to reach €15 billion globally by 2028, with pediatric CSU contributing approximately €300 million annually
- Competitive Edge: As the first biologic approved for pediatric CSU, Dupixent faces limited competition in this segment, with no other IL-4/IL-13 inhibitors approved for this indication
- Commercial Strategy: Sanofi plans to leverage existing dermatology and immunology sales infrastructure for rapid market penetration, with patient support programs to facilitate access
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory approvals, commercial expectations, and market opportunities for Dupixent. Actual results may differ due to risks including market adoption rates, reimbursement decisions, competitive developments, and evolving treatment guidelines.-Fineline Info & Tech